SE509694C2 - Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter - Google Patents

Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter

Info

Publication number: SE509694C2
Authority: SE; Sweden
Prior art keywords: composition according; methyl; bismuth; ranitidine; salt
Prior art date: 1990-09-11

Application number

SE9102604A

Other languages

English (en)

Swedish (sv)

Other versions

SE9102604L (sv

SE9102604D0 (sv

Inventor

Norman Richard Smith

Colin Roy Heppenstall

Stephen John Douglas

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-11

Filing date

1991-09-10

Publication date

1999-02-22

1991-09-10 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1991-09-10 Publication of SE9102604D0 publication Critical patent/SE9102604D0/xx

1992-03-12 Publication of SE9102604L publication Critical patent/SE9102604L/xx

1999-02-22 Publication of SE509694C2 publication Critical patent/SE509694C2/sv

Links

229960000620 ranitidine Drugs 0.000 title claims abstract description 13
229910052797 bismuth Inorganic materials 0.000 title claims abstract description 11
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 title claims abstract description 9
-1 bismuth carboxylic acid salts Chemical class 0.000 title claims description 9
239000008194 pharmaceutical composition Substances 0.000 title claims 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 7
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims abstract description 3
239000011975 tartaric acid Substances 0.000 claims abstract description 3
235000002906 tartaric acid Nutrition 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 39
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 34
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
229910000029 sodium carbonate Inorganic materials 0.000 claims description 14
159000000011 group IA salts Chemical class 0.000 claims description 12
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
150000001342 alkaline earth metals Chemical class 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
239000007787 solid Substances 0.000 claims 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
241001397173 Kali <angiosperm> Species 0.000 claims 1
LUOYFQVUYMMTRC-UHFFFAOYSA-N bismuth(3+) Chemical compound [Bi+3].[Bi+3] LUOYFQVUYMMTRC-UHFFFAOYSA-N 0.000 claims 1
XAUTYMZTJWXZHZ-UHFFFAOYSA-K bismuth;1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical group [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-UHFFFAOYSA-K 0.000 claims 1
125000005587 carbonate group Chemical group 0.000 claims 1
238000000354 decomposition reaction Methods 0.000 claims 1
238000004090 dissolution Methods 0.000 claims 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
238000002360 preparation method Methods 0.000 claims 1
150000001447 alkali salts Chemical class 0.000 abstract 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 32
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
239000004480 active ingredient Substances 0.000 description 18
235000019359 magnesium stearate Nutrition 0.000 description 16
239000003826 tablet Substances 0.000 description 15
239000001267 polyvinylpyrrolidone Substances 0.000 description 13
229920000036 polyvinylpyrrolidone Polymers 0.000 description 13
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000008187 granular material Substances 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 8
235000019813 microcrystalline cellulose Nutrition 0.000 description 8
239000008108 microcrystalline cellulose Substances 0.000 description 8
229940016286 microcrystalline cellulose Drugs 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
238000001035 drying Methods 0.000 description 7
239000008101 lactose Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(e)-1-n'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-n-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 3
229960004696 ranitidine bismuth citrate Drugs 0.000 description 3
KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
SULICOHAQXOMED-YDXPQRMKSA-H dibismuth;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Bi+3].[Bi+3].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O SULICOHAQXOMED-YDXPQRMKSA-H 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Furan Compounds (AREA)

SE9102604A 1990-09-11 1991-09-10 Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter SE509694C2 (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB909019875A GB9019875D0 (en)	1990-09-11	1990-09-11	Pharmaceutical compositions
NO920408A NO179694C (no)	1990-09-11	1992-01-30	Farmasöytiske preparater inneholdende ranitidinderivater
PCT/EP1992/000498 WO1993017679A1 (fr)	1990-09-11	1992-03-05	Composition contenant un sel du type carboxylate de bismuth et de ranitidine

Publications (3)

Publication Number	Publication Date
SE9102604D0 SE9102604D0 (sv)	1991-09-10
SE9102604L SE9102604L (sv)	1992-03-12
SE509694C2 true SE509694C2 (sv)	1999-02-22

Family

ID=47884627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9102604A SE509694C2 (sv)	1990-09-11	1991-09-10	Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter

Country Status (33)

Country	Link
US (1)	US5456925A (fr)
EP (1)	EP0558779B1 (fr)
JP (1)	JPH0692849A (fr)
KR (1)	KR100196308B1 (fr)
AT (2)	AT405134B (fr)
AU (2)	AU640816B2 (fr)
BE (1)	BE1005115A5 (fr)
BG (1)	BG61931B1 (fr)
CA (1)	CA2050970C (fr)
CH (1)	CH683068A5 (fr)
CY (1)	CY1988A (fr)
DE (2)	DE4130061A1 (fr)
DK (1)	DK159191A (fr)
ES (1)	ES2072647T3 (fr)
FI (1)	FI944047A0 (fr)
FR (1)	FR2666508B1 (fr)
GB (2)	GB9019875D0 (fr)
HK (1)	HK60894A (fr)
HU (1)	HU211846A9 (fr)
IE (1)	IE65049B1 (fr)
IL (1)	IL99428A (fr)
IT (1)	IT1249696B (fr)
MX (1)	MX9101009A (fr)
NL (1)	NL194907C (fr)
NO (1)	NO179694C (fr)
NZ (1)	NZ239731A (fr)
OA (1)	OA10093A (fr)
RO (1)	RO112084B1 (fr)
RU (1)	RU2108097C1 (fr)
SE (1)	SE509694C2 (fr)
SK (1)	SK279591B6 (fr)
WO (1)	WO1993017679A1 (fr)
ZA (1)	ZA917176B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019875D0 (en) *	1990-09-11	1990-10-24	Glaxo Group Ltd	Pharmaceutical compositions
GB9120131D0 (en) *	1991-09-20	1991-11-06	Glaxo Group Ltd	Medicaments
ES2130152T3 (es) *	1991-12-06	1999-07-01	Glaxo Group Ltd	Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
GB9127150D0 (en) *	1991-12-20	1992-02-19	Smithkline Beecham Plc	Novel treatment
CA2211873A1 (fr) *	1995-01-26	1996-08-01	Michael Droege	Composes de bismuth
GB9501560D0 (en) *	1995-01-26	1995-03-15	Nycomed Imaging As	Contrast agents
AU1513699A (en) *	1998-08-18	2000-03-14	Nikolai Borisovich Leonidov	Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
EP1104673A1 (fr) *	1999-11-30	2001-06-06	Bayer Classics	Composition pharmaceutique sans agent desintégrant contenant un bicarbonate
KR100412290B1 (ko) *	2001-11-27	2003-12-31	주식회사 동구제약	라니티딘 함유 현탁제 조성물 및 그의 제조방법
US20060100271A1 (en) *	2004-11-08	2006-05-11	Keith Whitehead	Stabilized aqueous ranitidine compositions
US9629809B2 (en)	2008-07-21	2017-04-25	Si Group, Inc.	High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
CA2730005C (fr)	2008-07-21	2017-06-13	Albermarle Corporation	Granules d'ibuprofene sodique a teneur, leur preparation et leur utilisation dans la preparation de formes posologiques solides non effervescentes
US20230218663A1 (en) *	2020-06-01	2023-07-13	The University Of Hong Kong	Compositions and methods for treating a sars-cov-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4608257A (en) *	1984-01-03	1986-08-26	Board Of Regents For Oklahoma State University	Composition and method for treating heat stress
GB8629781D0 (en) *	1986-12-12	1987-01-21	Glaxo Group Ltd	Pharmaceutical compositions
EP0282132B1 (fr) *	1987-03-09	1992-09-30	The Procter & Gamble Company	Compositions et leur utilisation dans le traitement d'affections gastrointestinales
DE3710462A1 (de) *	1987-03-30	1988-10-13	Heumann Pharma Gmbh & Co	Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
FR2633181B1 (fr) *	1988-06-24	1992-01-10	Glaxo Lab Sa	Composition pharmaceutique a base de ranitidine et son procede de preparation
CH679582A5 (fr) *	1988-07-18	1992-03-13	Glaxo Group Ltd
EP0363502B1 (fr) *	1988-10-08	1991-09-25	Dr. R. Pfleger Chemische Fabrik Gmbh	Formulation liquide contenant du bismuth, procédé pour la préparer et son utilisation
AU641903B2 (en) *	1988-10-26	1993-10-07	Glaxo Group Limited	Carboxylic acid derivatives
US5013560A (en) *	1989-03-17	1991-05-07	The Procter & Gamble Company	Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) *	1990-09-11	1990-10-24	Glaxo Group Ltd	Pharmaceutical compositions

1990
- 1990-09-11 GB GB909019875A patent/GB9019875D0/en active Pending
1991
- 1991-09-06 IL IL9942891A patent/IL99428A/en not_active IP Right Cessation
- 1991-09-09 CA CA002050970A patent/CA2050970C/fr not_active Expired - Fee Related
- 1991-09-10 DK DK159191A patent/DK159191A/da not_active Application Discontinuation
- 1991-09-10 ZA ZA917176A patent/ZA917176B/xx unknown
- 1991-09-10 FR FR9111146A patent/FR2666508B1/fr not_active Expired - Fee Related
- 1991-09-10 CH CH2655/91A patent/CH683068A5/fr not_active IP Right Cessation
- 1991-09-10 JP JP3230571A patent/JPH0692849A/ja active Pending
- 1991-09-10 IT ITRM910673A patent/IT1249696B/it active IP Right Grant
- 1991-09-10 IE IE319191A patent/IE65049B1/en not_active IP Right Cessation
- 1991-09-10 GB GB9119284A patent/GB2248185B/en not_active Expired - Fee Related
- 1991-09-10 KR KR1019910015760A patent/KR100196308B1/ko not_active IP Right Cessation
- 1991-09-10 SE SE9102604A patent/SE509694C2/sv not_active IP Right Cessation
- 1991-09-10 AU AU83757/91A patent/AU640816B2/en not_active Ceased
- 1991-09-10 BE BE9100841A patent/BE1005115A5/fr not_active IP Right Cessation
- 1991-09-10 NZ NZ239731A patent/NZ239731A/en unknown
- 1991-09-10 NL NL9101533A patent/NL194907C/nl not_active IP Right Cessation
- 1991-09-10 DE DE4130061A patent/DE4130061A1/de not_active Withdrawn
- 1991-09-10 AT AT0180191A patent/AT405134B/de not_active IP Right Cessation
1992
- 1992-01-30 NO NO920408A patent/NO179694C/no not_active IP Right Cessation
- 1992-03-05 MX MX9101009A patent/MX9101009A/es unknown
- 1992-03-05 DE DE69202696T patent/DE69202696D1/de not_active Expired - Lifetime
- 1992-03-05 RO RO94-01459A patent/RO112084B1/ro unknown
- 1992-03-05 EP EP92103741A patent/EP0558779B1/fr not_active Expired - Lifetime
- 1992-03-05 AU AU13347/92A patent/AU1334792A/en not_active Abandoned
- 1992-03-05 AT AT92103741T patent/ATE122883T1/de not_active IP Right Cessation
- 1992-03-05 WO PCT/EP1992/000498 patent/WO1993017679A1/fr active IP Right Grant
- 1992-03-05 SK SK1060-94A patent/SK279591B6/sk unknown
- 1992-03-05 ES ES92103741T patent/ES2072647T3/es not_active Expired - Lifetime
- 1992-03-05 RU RU94040869A patent/RU2108097C1/ru active
1994
- 1994-03-22 US US08/215,658 patent/US5456925A/en not_active Expired - Lifetime
- 1994-06-23 HK HK60894A patent/HK60894A/xx not_active IP Right Cessation
- 1994-08-12 OA OA60553A patent/OA10093A/en unknown
- 1994-09-01 BG BG99021A patent/BG61931B1/bg unknown
- 1994-09-02 FI FI944047A patent/FI944047A0/fi unknown
1995
- 1995-06-28 HU HU95P/P00511P patent/HU211846A9/hu unknown
1997
- 1997-09-05 CY CY198897A patent/CY1988A/en unknown

Also Published As

Publication number	Publication date
NL194907C (nl)	2003-07-04
NL9101533A (nl)	1992-04-01
IT1249696B (it)	1995-03-09
KR100196308B1 (ko)	1999-06-15
SK106094A3 (en)	1995-02-08
GB2248185A (en)	1992-04-01
NO920408L (no)	1993-08-02
US5456925A (en)	1995-10-10
FR2666508B1 (fr)	1994-02-18
GB2248185B (en)	1994-02-02
ATE122883T1 (de)	1995-06-15
ATA180191A (de)	1998-10-15
RU2108097C1 (ru)	1998-04-10
NO179694C (no)	1996-12-04
CA2050970A1 (fr)	1992-03-12
NO920408D0 (no)	1992-01-30
NZ239731A (en)	1993-10-26
IL99428A (en)	1996-06-18
IE65049B1 (en)	1995-10-04
GB9119284D0 (en)	1991-10-23
CH683068A5 (fr)	1994-01-14
DK159191D0 (da)	1991-09-10
FI944047A (fi)	1994-09-02
RO112084B1 (ro)	1997-05-30
EP0558779A1 (fr)	1993-09-08
EP0558779B1 (fr)	1995-05-24
NO179694B (no)	1996-08-26
MX9101009A (es)	1992-05-04
CY1988A (en)	1997-09-05
KR920005984A (ko)	1992-04-27
AU640816B2 (en)	1993-09-02
DK159191A (da)	1992-03-12
WO1993017679A1 (fr)	1993-09-16
FR2666508A1 (fr)	1992-03-13
BE1005115A5 (fr)	1993-04-27
JPH0692849A (ja)	1994-04-05
AU1334792A (en)	1993-10-05
IL99428A0 (en)	1992-08-18
ITRM910673A0 (it)	1991-09-10
HU211846A9 (en)	1995-12-28
SK279591B6 (sk)	1999-01-11
ITRM910673A1 (it)	1993-03-10
AT405134B (de)	1999-05-25
ES2072647T3 (es)	1995-07-16
HK60894A (en)	1994-07-08
CA2050970C (fr)	2002-11-19
AU8375791A (en)	1992-03-19
GB9019875D0 (en)	1990-10-24
DE4130061A1 (de)	1992-03-12
OA10093A (en)	1996-12-18
NL194907B (nl)	2003-03-03
SE9102604L (sv)	1992-03-12
BG61931B1 (bg)	1998-10-30
SE9102604D0 (sv)	1991-09-10
FI944047A0 (fi)	1994-09-02
DE69202696D1 (de)	1995-06-29
IE913191A1 (en)	1992-04-22
ZA917176B (en)	1992-06-24
BG99021A (bg)	1995-06-30

Publication	Publication Date	Title
US5529783A (en)	1996-06-25	Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
RU2142790C1 (ru)	1999-12-20	Фармацевтическая композиция, стабилизированная основным агентом
HU193434B (en)	1987-10-28	Process for producing antibiotic compositions of retarde activity
SE509694C2 (sv)	1999-02-22	Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter
US4370313A (en)	1983-01-25	Nitrofurantoin dosage form
US3865935A (en)	1975-02-11	Tableting of erythromycin base
CA2361843C (fr)	2008-10-14	Comprimes a avaler a teneur elevee en n-acetylcysteine
US3891755A (en)	1975-06-24	Dosage formulation for erythromycin cetyl sulfate
EP2117534B1 (fr)	2011-10-05	Composition pharmaceutique à principe actif atorvastatine
JP4845087B2 (ja)	2011-12-28	経口投与用製剤
HUT67577A (en)	1995-04-28	Process for production of adsorbate comprising adjuvant-mixture and non-solid active agent using production of preparations
HU217587B (hu)	2000-02-28	Ranitidint és bizmut-karboxilát-komplexet, valamint bázisos sókat tartalmazó gyógyászati készítmények
RU2240112C1 (ru)	2004-11-20	Лекарственная форма, обладающая бактериостатическим действием, и способ ее изготовления
CN113679687A (zh)	2021-11-23	一种复合释药组合物、口崩片组合物和口崩制剂及其应用
CZ209794A3 (en)	1994-12-15	Pharmaceutical preparation

Legal Events

Date	Code	Title	Description
2003-05-06	NUG	Patent has lapsed